Advertising
Showing 1 to 15 of 21 entries
BUY
A fast-growing telehealth company and are pushing hard into enterprise health solutions by offering a one-stop patient approach to the primary care and mental health sectors. They are integrating several acquisitions. They are guiding to an EBITDA of $10 million this year which they could surpass. This sector has been almost left for dead, but the digital revolution in health has just begun so now is the time to enter it.
Healthcare
BUY
One of the fastest healthcare technology companies. Expanding into enterprise health solutions space. Expecting strong financial results in 2022. Low stock price presenting good buying opportunity.
Healthcare
STRONG BUY
One of two he owns in the health care sector. Digitization within health care has only just begun. The last quarter beat expectations. They announced a large deal with Sun Life on mental health coaching. This alone could be $40 million in annual revenues. Things are going in the right direction and will exceed expectations next year. A very good entry point here.
Healthcare
BUY
Pre-announced today that revenues will be higher than forecast. Encouraging, as there's significant organic growth in addition to acquisitions. Likes the strategy. Will probably be one of the few telehealth winners. Lots of strings to their bow. Good time to buy. Sky's the limit on target prices for this sector. Good long-term hold.
Healthcare
BUY on WEAKNESS
Small caps have seen some correction, but the underlying fundamentals are growing. The business continues to move forward. What was considered telemedicine has now extended out to more services, such as employer plans. Top line growth is around 10% per quarter. They are profitable and has large cash positions to make acquisitions. Trading at half the valuation of WELL.
Healthcare
BUY
Exciting play on telemedicine. Entire sector is pricey, but good upside opportunity if the trends continue. The whole concept makes a lot of sense. Good sector to have some exposure to. He owns a small position.
Healthcare
TOP PICK
It is one of the fastest growing healthcare solutions providers. They made a series of very targeted acquisitions which they are integrating. A quality company with quality assets. (Analysts’ price target is $4.19)
Healthcare
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenue grew by 461% year over year. However, EPS missed estimates. It is growing extremely fast and organic growth is forecasted to be driven by partner relationships. The balance sheet is growing rapidly and top-line growth should outpace operating expenses. Unlock Premium - Try 5i Free

Healthcare
DON'T BUY
It was caught up with other health care names when COVID hit. The company got a little ahead of itself with the excitement of remote medicine. They raised a lot of capital and acquired a lot of companies. It is a wait-and-see for him. They need to justify the valuation that it is at now. He prefers others.
Healthcare
TOP PICK
Telemedicine plus they use AI in their medical clinics. They make acquisitions to synergize and they grow organically. They boast $130 in revenue and $50 million in cash, so they can continue to buy more companies. It trades at 2.5x revenue vs.peers at 6x. Expect good multiple appreciation. Managers own a lot of stock and he's known them from the start. They execute well. They should rise a lot higher. (Analysts’ price target is $3.96)
Healthcare
TOP PICK
Healthcare solution providers. Acquisitions and organic growth. Really likes the recent push of one-stop healthcare shopping to employers and insurance companies. Sector has come down, waiting for two deals to close, trading at 3x profitable revenues. Great opportunity. No dividend. (Analysts’ price target is $3.96)
Healthcare
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It reported strong revenue growth at $8.8M. An increase of 187% YoY. They made 5 acquisitions and is well-capitalized to pursue more. There is also organic growth in all parts of the business. Long term outlook looks good. Unlock Premium - Try 5i Free

Healthcare
DON'T BUY
Loss of 2 cents this year, gain of 2 cents next year. Telemedicine is a fantastic opportunity, but not a lot of barriers to entry, and the big guys are already involved. He favours companies with high barriers to entry. PE of 100, so he'd pass.
Healthcare
PAST TOP PICK
(A Top Pick Apr 27/20, Up 282%) Tele-medicine. Expanded through Canada and now into US. Trading at lower valuation than peers. Just raised capital for more acquisitions of technology and clinics.
Healthcare
BUY on WEAKNESS
They are doing a lot of interesting things. He decided to take a position in another in the space. The problem was the valuation. It is too expensive. It is a promising space in the long run. It is expensive right now but a well managed company. You need to buy it cheaply and smartly.
Healthcare
Showing 1 to 15 of 21 entries

CloudMD(DOC-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 10

Stockchase rating for CloudMD is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CloudMD(DOC-X) Frequently Asked Questions

What is CloudMD stock symbol?

CloudMD is a Canadian stock, trading under the symbol DOC-X on the TSX Venture Exchange (DOC-CV). It is usually referred to as TSXV:DOC or DOC-X

Is CloudMD a buy or a sell?

In the last year, 10 stock analysts published opinions about DOC-X. 8 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for CloudMD.

Is CloudMD a good investment or a top pick?

CloudMD was recommended as a Top Pick by on . Read the latest stock experts ratings for CloudMD.

Why is CloudMD stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CloudMD worth watching?

10 stock analysts on Stockchase covered CloudMD In the last year. It is a trending stock that is worth watching.

What is CloudMD stock price?

On 2022-05-27, CloudMD (DOC-X) stock closed at a price of $0.41.